

经皮冠脉介入术联合替格瑞洛治疗 ACS 的临床观察

卢晓海

北京市昌平区医院 北京 102200

【摘要】: 目的: ACS PCI + 方法: 2020 7 2021 8
ACS 98 PCI 49 结果:
PRU NO sCD40L ET-1 MPAR MMP-9 hs-CRP
QT P<0.05 P>0.05 结论: PCI ACS

【关键词】: ACS

Clinical Observation of Percutaneous Coronary Intervention Combined with Ticagrelor in the Treatment of ACS

Xiaohai Lu

Beijing Changping District Hospital Beijing 102200

Abstract: Objective: To observe the effect of percutaneous coronary intervention (PCI) + ticagrelor in the treatment of ACS. Methods: A total of 98 patients with ACS who were treated from July 2020 to August 2021 were selected, and all of them received PCI treatment and were randomly divided into an observation group (ticagrelor) and a control group (clopidogrel sulfate), 49 cases in each group, and the effects were compared. Results: The levels of PRU, NO, sCD40L, ET-1, MPAR, MMP-9, hs-CRP, fasting blood glucose, plasma crystal osmolality and QT dispersion in the observation group were lower than those in the control group. (P<0.05); comparison of bleeding between the two groups (P>0.05). Conclusion: PCI combined with ticagrelor can effectively improve the platelet function and inflammation level in ACS, reduce the probability of rebleeding, and regulate the osmotic pressure of plasma crystalloid.

Keywords: ACS; Platelet function; Percutaneous coronary intervention; Inflammatory index; Ticagrelor
PCI

^[1] ACS H20123115 300mg 1 /d 75mg 1 /d
PCI ACS H20183320 180mg
PCI ^[2] 2 /d 90mg 2 /d 30
ACS PCI 1.3 P2Y₁₂ PRU
1 资料和方法 40 sCD40L MPAR
1.1 98 ACS 2020 7 2021 8 60.52± 0.32 -9 MMP-9 NO -1 ET-1
49 26 23 59.48± hs-CRP MACE
49 27 22 QT
0.29 P>0.05
1.2 1.4

SPSS18.0 MACE
 % χ^2
 QT \bar{x}

$\pm s$ t P 0.05

ADP P2Y12

2 结果

2.1

P>0.05 P<0.05

P2Y12

1

G

P2Y12

1 $\bar{x} \pm s$

		PRU(u)		sCD40L(g/L)		MPAR(%)	
	49	231.75±21.84	121.32±12.55	3.87±1.16	2.85±0.9	59.8±5.61	36.3±8.386
	49	227.29±21.26	152.27±14.37	3.91±1.22	3.27±1.03	59.3±5.75	41.2±7.430
t		0.552	5.726	0.715	6.336	0.362	9.365
P		>0.05	<0.05	>0.05	<0.05	>0.05	<0.05

3 讨论

ACS

ACS

PCI

QTd

QTd

PCI MACE

QTd

CYP

1

CYP2C19

2 ACS

40%

3

P2Y12

[3]

PCI

4

ACS

PCI+

参考文献:

[1] ACS PCI [J]. 2022,44(13):1982-1984,1988.

[2] ACS PCI [J]. 2019,43(11):1721-1722.

[3] ACS PCI [J]. 2021,23(5):495-498.

[4] ACS PCI [J]. 2021,18(2):41-44.

[5] ACS PCI [J]. 2022,50(5):443-449.

[6] ACS PCI [J].